Clinical trials: Induction Chemotherapy
Triple Negative Breast Cancer, Breast Cancer
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
The purpose of this study is to evaluate the mechanism of action, as well as the safety and efficacy of trilaciclib in combination with standard of care treatment in the neoadjuvant setting of early-stage triple negative breast…
- Trial name
- NCT05112536
- Testing
- Trilaciclib, Cylophosphamide, Doxorubicin
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- G1 Therapeutics, Inc.
Purpura, Thrombocytopaenic, Idiopathic
Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment
The main purpose of this study is to compare how one 50 mg tablet of SB-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe kidney problems.
- Trial name
- NCT00442871
- Testing
- eltrombopag
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small-Cell Lung
Concomitant Chemo-radiotherapy in Locally Advanced Non Small Cell Lung Cancer
Feasibility of pragmatic concomitant chemo-radiotherapy association with 1 cycle of Induction chemotherapy, weekly chemo-radiotherapy, and consolidation chemotherapy.
- Trial name
- BIB 01 (NCT00210171)
- Testing
- Toxicity : Time to progression, 1 and 2 years survival
- Where
- 7 sites in France
- Sponsor
- Institut Bergonié
Chemotherapy-induced Nausea and Vomiting
NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer
This study evaluates if the activity of one-day of NEPA plus dexamethasone, to prevent chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant AC-based chemotherapy, is maintained during all the…
- Trial name
- GIM15-NEPA (NCT03862144)
- Testing
- Netupitant/Palonosetron
- Volunteers
- 150 people
- Sponsor
- Consorzio Oncotech
Thrombocytopenia, Primary Thrombocytopenia,Unspecified
Protocol for the Infusion of Buffy Coat-derived Cryopreserved Platelets in Patients With Severe Thrombocytopenia
The increasing need for blood components and the increasingly careful donor selection procedures, make the availability of blood components very reduced, in particular for platelets that are currently administered preferably…
- Conditions
- Thrombocytopenia, Primary Thrombocytopenia,Unspecified, Thrombocytopenia Chemotherapy Induced
- Trial name
- MICE (NCT02032134)
- Testing
- Transfusion of Pooled Platelets Cryopreserved In DMSO
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- Napolitano Mariasanta
Neurotoxicity, Gastrointestinal Neoplasms
Clinical Trial of Electroacupuncture Stimulation on Prevention and Treatment of Oxaliplatin Neurotoxicity
The clinical trail of electroacupuncture combined with oxaliplatin regimen on gastrointestinal carcinoma.This trail is randomized controled.Patients are diagnosed gastrointestinal cancer based on pathology or cell biology.They…
- Trial name
- NCT03330964
- Testing
- electro-acupuncture
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
Localized Small Cell Lung Cancer
Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone
Observation and Evaluation of the Efficacy and Safety of Adalimumab Combined with Chemotherapy Followed by Radiotherapy or Radiotherapy Alone as First-Line Treatment for Limited-Stage Small Cell Lung Cancer
- Trial name
- NCT07381543
- Testing
- Adebrelimab Induction Therapy Group, Adebrelimab Maintenance Therapy Group
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Peking University Cancer Hospital & Institute
Advanced Nasopharyngeal Carcinoma
GP-induced Chemotherapy Combined With IMRT and TPF-induced Chemotherapy Combined With IMRT in the Treatment of Distant Metastatic Nasopharyngeal Carcinoma
Mainly compared with GP induction chemotherapy combined with IMRT and TPF induction chemotherapy combined with IMRT in the treatment of nasopharyngeal carcinoma, the cure rate, remission rate, treatment of distant metastases and…
- Trial name
- NCT03723343
- Testing
- GP+IMRT, TPF+IMRT
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Guiyang Medical University
Multiple Myeloma
Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old
This protocol is a national, multicenter, comparative, open-label, randomized trial comparing the progression free survival (PFS) of two pre-transplant conditioning regimens (BUMEL versus. MEL-200).
- Trial name
- GEM2012MENOS65 (NCT01916252)
- Testing
- bortezomib (Velcade ®), lenalidomide (Revlimid®), busulfan (Busilvex ®)
- Where
- 74 sites in Spain
- Volunteers
- 460 people
- Sponsor
- PETHEMA Foundation
Chemotherapy-induced Peripheral Neuropathy, Nerve Pain
The Effect of Yoga on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)
The purpose of this study is to test whether yoga can reduce nerve pain caused by cancer treatment (chemotherapy-induced peripheral neuropathy, or CIPN).
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Nerve Pain, Neuropathy, Neuropathy, Painful
- Trial name
- YCT (NCT05121558)
- Testing
- Yoga, Education control, Usual care
- Where
- 8 sites in United States
- Volunteers
- 227 people
- Sponsor
- Dana-Farber Cancer Institute
Alopecia
Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)
Phase II clinical trial
- Trial name
- ELAN (NCT02919735)
- Testing
- CG 428 cutaneous solution
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Legacy Healthcare SA
High-Risk Cancer, Locally Advanced Breast Cancer
Three Fraction Radiation to Induce Immuno-Oncologic Response
Patients with high risk breast cancers (any locally advanced breast cancer patient defined as Stages IIB-III [excluding inflammatory breast cancer] with stage IIA being eligible for triple negative and HER2-positive breast…
- Trial name
- TRIO (NCT03978663)
- Testing
- Neoadjuvant radiotherapy
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NSCLC Stage IIIB, Concomitant Radiochemotherapy
Chemoradiotherapy of NSCLC Stage IIIB
To evaluate the best timing of the concomitant chemoradiotherapy among patients with NSCLC stage III not resectable treated by concomitant chemo-radiotherapy, either preceded by a induction chemotherapy, or followed by a…
- Trial name
- NCT00198432
- Testing
- Paclitaxel, vinorelbine, cisplatin
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
Activating mutations in the fms like tyrosine kinase 3 (FLT3) gene are observed in approximately 30% of patients with newly diagnosed acute myeloid leukemia (AML).
- Trial name
- HOVON 156 AML (NCT04027309)
- Testing
- Gilteritinib, Midostaurin
- Where
- 193 sites in Australia, Austria and 11 more
- Volunteers
- 777 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Severe Thrombocytopenia
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
This is an open-label study in which oprelvekin will be administered for the prevention of severe low blood platelet cell counts (cells in your blood that keep bleeding and clotting stable) in adults with cancer who are taking…
- Trial name
- NCT00886743
- Testing
- oprelvekin
- Where
- 14 sites in United States
- Volunteers
- 19 people
- Sponsor
- Pfizer
Leukemia, Myeloid, Acute
NLA101 in Adults Receiving High Dose Chemotherapy for AML
Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML.
- Trial name
- LAUNCH (NCT03301597)
- Testing
- NLA101, Standard of Care (SOC) chemotherapy
- Where
- 36 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Nohla Therapeutics, Inc.
Head and Neck Cancer
Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- CAPRA (NCT01333085)
- Testing
- carboplatin, RAD001, paclitaxel
- Where
- 5 sites in France
- Volunteers
- 49 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Morquio Disease
Establishment of Human Cellular Disease Models for Morquio Disease
Establishment of human cellular disease models for Morquio disease for an individualized therapy development having the capacity to address both hepatic and neurologic forms of the disease
- Trial name
- IPSMORQUIO (NCT03872713)
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- CENTOGENE GmbH Rostock
Breast Cancer, Chemotherapy-induced Peripheral Neuropathy (CIPN)
Chinese Medicinal Component Relieves CIPN and Mitochondria Function
A randomized controlled trial was designed and conducted to confirm whether oral administration of the herb Moutan Cortex, which contains paeonol, can alleviate peripheral neuropathy in paclitaxel-treated cancer patients.
- Trial name
- NCT07693374
- Testing
- Moutan cortex
- Where
- Taiwan
- Sponsor
- Taiwan Municipal An-Nan Hospital-China Medical University
Cardiotoxicity, Risk Factor, Cardiovascular
Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
Investigators will evaluate the safety, tolerability, and feasibility of a risk-guided cardioprotective treatment strategy with carvedilol, as compared to usual care, in breast cancer patients undergoing treatment with…
- Conditions
- Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer
- Trial name
- CCTGuide Pilot (NCT04023110)
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.